Skip to main content

Posts

Showing posts with the label pharma

Tensions In Innovation, 2013

Forbes :  "...it’s hard not to worry that if medicine goes in the direction of the Cheesecake Factory, where care is administered on the cheap by customer-service technologists plugging data into an algorithm, then an ancient and noble profession will face extinction because of an inability (some might say a haughty unwillingness) to adequately contemplate and communicate its essential value proposition." 

Who Is Really At-Risk Here?

An item from yesterday's Wall Street Journal caught my wandering eye. Though the economy's sad state continues to depress healthcare utilization, the effect is markedly different depending on your place in the food chain. UnitedHealthcare's earnings are up as declining utilization has not (yet) resulted in declining premiums (though come to think of it, when has it ever?)  It's no surprise that payers benefit when utilization drops.  The difference here is that the economy's doing their dirty work for them. On the other hand, Johnson & Johnson's earnings are down as consumers decide they can live without Band-Aids and Tylenol, and cash-strapped hospitals clamp down on expensive artificial joints.  Getting paid "per-click" is great when volume heats up, not so much fun when the movie runs backwards. And, no, this is not what providers mean when they mention "downside risk."  That's an entirely DIFFERENT way to lose a ton of m...

The Weekend In Ideas and Innovation

Booz&Co: Middle managers hold the key to reinvigorating a stalled innovation pipeline. H&HN Daily:   Can your hospital handle the truth? ArgusLeader.com : Biotech startup pharmaCline launches its first-aid antibiotic topical ointment venture in S.F.  You're probably not surprised, except here it's Sioux Falls, SD. NY Times : Medical school should be free. MedCity News: 27 million Americans battle osteoarthritis. Now, Madison, Wisconsin-based Flex Biomedical may have a "disruptive technology" for improved treatment.  Human trials begin next year as the company seeks $5 million from a strategic investor. Also from MedCity News : How relevant are VCs and their money to early-stage med tech startups?  Pharmacogenomics Reporter: Clayton Christensen develops his disruptive innovation theory into a Roadmap for Personalized Health Care.  Look for an online release later this year.  More from Christensen at Forbes.com ; "Companies do not rout...

More R&D Funding Equals More Innovation, Right?

Wrong.  From Carl Schramm at Forbes : "In the past 15 years, despite a doubling of federal funds for biomedical R&D, the number of new drugs approved by the FDA and coming to market has decreased by nearly half — from around 40 per year in the late 1990s to a little over 20 per year since 2005. Pre-market testing to meet FDA requirements has become such a huge factor in drug development budgets that it’s hard for companies to even consider working on new products with limited market potential." Biomedical innovations are likely to come first to market in faster-moving regions - Singapore, the more progressive Arab states, perhaps India and China.  Health providers may think this is Big Pharma's problem to solve.  They're wrong.  Anything encouraging medical tourism - as earlier access to life-saving innovations certainly does - is one more hole in the bottom of providers' already-leaky lifeboat.  It's in everybody's interest to see that innovation ...

Are the Bugs Winning?

As bacteria get craftier and deadlier, the Obama administration considers incentives - tax breaks, patent extensions, etc. - to coax Big Pharma back into the antibiotic development business. Serious stuff.  And next time you're at your doctor's office with what's probably a virus, refrain from asking for a Cipro prescription.  You're just contributing to the problem.  Keep it up and someday it won't work at all, maybe when you really need it.
"$112 billion...in lost sales (a 4.3% decline) are projected for pharma manufacturers over the next nine years as the provisions of health reform begin to take effect, according to a new report from PricewaterhouseCoopers." ( Via AIS's Health Business Daily )